The role of bevacizumab in combination with pegylated liposomal doxorubicin in patients with platinum-resistant recurrent or refractory ovarian cancers.
H. Kouta
No relevant relationships to disclose
K. Kudoh
No relevant relationships to disclose
M. Takano
No relevant relationships to disclose
R. Kikuchi
No relevant relationships to disclose
T. Kita
No relevant relationships to disclose
T. Goto
No relevant relationships to disclose
K. Furuya
No relevant relationships to disclose
Y. Kikuchi
No relevant relationships to disclose